← FDA DRUG APPROVALS

FDA ANDA · ANDA217041

SITAGLIPTIN

Sponsor: FOSUN WANBANG (JIANGSU) PHARMACEUTICAL GROUP CO.,

APPLICATION
ANDA217041
TYPE
ANDA
DOSAGE FORM
TABLET
MARKETING STATUS
None (Tentative Approval)

Products

SITAGLIPTINNone (Tentative Approval)
SITAGLIPTIN PHOSPHATE 100MG · TABLET
SITAGLIPTINNone (Tentative Approval)
SITAGLIPTIN PHOSPHATE 50MG · TABLET

Approval history

2026-01-26UNKNOWN · Original · standardTA
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →